首页|益消方经转化生长因子β1信号通路干预糖尿病合并脂肪肝的实验研究

益消方经转化生长因子β1信号通路干预糖尿病合并脂肪肝的实验研究

扫码查看
目的:探索益消方对糖尿病合并脂肪肝的影响和作用机制.方法:观察组为12周龄雄性自发糖尿病(KKAy)小鼠,按照随机数字表法随机分为模型组、中药组(益消方干预)、西药组(氯沙坦干预);对照组为同周龄雄性近交系(C57BL/6J)小鼠.干预周期为12周.观察干预前后血糖、血脂-、肝功能变化,肝脏组织进行病理染色,检测肝脏组织转化生长因子β1,(TGF-β1)信号通路蛋白和信使核糖核酸(mRNA)的变化.结果:与模型组比较,益消方干预8周体质量、肝重指数显著降低(P<0.05,P<0.01),干预第4、8、12周空腹血糖显著降低(P<0.01),干预8周胆固醇、三酰甘油、低密度脂蛋白胆固醇、谷丙转氨酶水平降低(P<0.05,P<0.01).病理形态方面益消方干预4周脂肪变性评分下降(P<0.05).益消方干预12周后,TGF-β1及其信号蛋白、mRNA的表达均显著下调(P<0.05,P<0.01).结论:益消方可显著改善KKAy小鼠的肥胖和糖脂代谢紊乱,调节TGF-β1信号通路蛋白和基因表达,减轻肝脏脂肪变性.
Intervention of Yixiao Formula in Diabetes Combined with Fatty Liver Through Transforming Growth Factor-β,Signaling Pathway
Objective:To explore the effects and mechanisms of Yixiao Formula on diabetes combined with fatty liver.Methods:Twelve-week-old male spontaneous diabetic(KKAy)mice were randomly divided into a model group,a Chinese medicine(Yixiao Formula)intervention group,and a Western medicine(losartan)intervention group using a random number table.The control group consisted of age-matched male inbred(C57BL/6J)mice.The intervention period lasted 12 weeks.Changes in blood glucose,blood lipids,and liver function were observed before and after the intervention.Liver tissue was pathologically stained,and changes in pro-teins and mRNAs in transforming growth factor-β1(TGF-β1)signaling pathway in liver tissues were detected.Results:Compared to the model group,the Yixiao Formula group showed a significant reduction in body weight and liver index after 8 weeks of interven-tion(P<0.05,P<0.01).Fasting blood glucose levels significantly decreased at 4,8,and 12 weeks of intervention(P<0.01).Af-ter 8 weeks of intervention,cholesterol,triglycerides,low-density lipoprotein cholesterol,and alanine aminotransferase levels were reduced(P<0.05,P<0.01).Pathologically,the steatosis score decreased after 4 weeks of Yixiao Formula intervention(P<0.05).After 12 weeks of intervention,the protein and mRNA expression of TGF-β1 was significantly downregulated(P<0.05,P<0.01).Conclusion:Yixiao Formula can significantly improve obesity and glucose-lipid metabolism disorders in KKAy mice,regu-late protein and gene expression in TGF-β1 signaling pathway,and reduce liver steatosis.

Yixiao FormulaDiabetesFatty liverGlucose and lipid metabolismTGF-β1/Smads signaling pathwayLosartanKKAy miceExperimental research

王姗、黄举凯、温雅璐、唐茹梦、王建华、杨晓晖

展开 >

北京中医药大学,北京,100029

聊城市中医医院,聊城,252000

北京中医药大学东直门医院,北京,100700

首都儿科研究所,北京,100020

展开 >

益消方 糖尿病 脂肪肝 糖脂代谢 转化生长因子β1/Smads信号通路 氯沙坦 KKAy小鼠 实验研究

国家自然科学基金项目

81974541

2024

世界中医药
世界中医药学会联合会

世界中医药

CSTPCDCHSSCD北大核心
影响因子:1.266
ISSN:1673-7202
年,卷(期):2024.19(11)
  • 9